FDA Delays Approval of Replimune’s Melanoma Therapy Despite Promising Trial Results
For now, the FDA has denied approval today of a new melanoma treatment developed by Replimune. The company’s lead drug...
Melanoma
First Eye-Saving Proton Therapy for Melanoma Launches in China
BEIJING, July 14, 2025 /PRNewswire/ -- Concord Healthcare Group Co., Ltd. ("Concord Healthcare"), a subsidiary of Concord Medical Services Holdings...
